-transparent.png){kind=logo}
Immunosuppressive agents serve a major role in the management of once-fatal conditions such as the systemic necrotizing vasculitides, but they are also being used in more common, chronic inflammatory disorders such as rheumatoid arthritis. The drugs are all capable of reducing cell division but they differ in their modes of action. This is in keeping with their differing rates of action, and different indications. Azathioprine is a valuable alternative to slow-acting antirheumatic drugs in older patients with rheumatoid arthritis. Cyclophosphamide has transformed the outlook of many forms of vasculitis. Chlorambucil is particularly useful in improving the prognosis for children with amyloidosis secondary to juvenile chronic arthritis. We have tried to highlight the role of these drugs in a number of rheumatic diseases. We have emphasized their clinical applications, with some laboratory evidence for their effects. The major side-effects are reviewed. Finally, we have discussed their possible mechanisms of action.
R A Luqmani, and
R G Palmer, and
P A Bacon
January 1981,
Voprosy revmatizma,
R A Luqmani, and
R G Palmer, and
P A Bacon
February 1979,
The British journal of dermatology,
R A Luqmani, and
R G Palmer, and
P A Bacon
December 1987,
Cancer treatment reports,
R A Luqmani, and
R G Palmer, and
P A Bacon
May 2012,
Journal of clinical pharmacology,
R A Luqmani, and
R G Palmer, and
P A Bacon
January 1975,
Archives of internal medicine,
R A Luqmani, and
R G Palmer, and
P A Bacon
July 1979,
Transplantation,
R A Luqmani, and
R G Palmer, and
P A Bacon
July 2003,
Seminars in nephrology,
R A Luqmani, and
R G Palmer, and
P A Bacon
February 1978,
The British journal of dermatology,
R A Luqmani, and
R G Palmer, and
P A Bacon
January 1979,
Neurologija,
R A Luqmani, and
R G Palmer, and
P A Bacon
July 1974,
JAMA,
